CKD and cardiovascular disesae (CVD) risk

CKD and cardiovascular disesae (CVD) risk
Wheeler, David
, , ,

Professor of Kidney Medicine at University College London, UK. A Clinician Scientist with an interest in the complications of chronic kidney disease, specifically those that increase the burden of cardiovascular disease and/or accelerate progression of kidney failure. Has participated in the design, roll out and monitoring of several large-scale clinical trials including the Study of Heart and Renal Protection (SHARP), the EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events (EVOLVE) and Canaglifozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE), acting at UK Chief Investigator for these studies.
Clinical Lead for Division 2 of the North Thames Clinical Research Network. Involvement in Guideline Development for several organisations, most recently for Kidney Disease, Improving Global Outcomes, of which he is currently co-chair. Past President of the Renal Association. Leads a team of 9 clinical Trials nurses/Practitioners involved at the Centre for Nephrology, Royal Free Hospital. Associate Editor of Nephrology, Dialysis Transplantation and Member of the Editorial Board of JASN.

Send Message to listing owner

CKD and cardiovascular disesae (CVD) risk